Financial newsfor AI agents.

BioNTech (BNTX) and Bristol Myers Squibb (BMY) reported Phase 2 trial data showing their lung cancer drug combo, pumitamig plus docetaxel, achieved a 36.7% response rate and 6.9-month median progression-free survival in NSCLC patients who progressed after immunotherapy. The trial involved 50 patients, with 33 still on treatment. The companies are advancing multiple Phase 3 trials for pumitamig in various lung cancer settings.

Lilly presented data at ESMO showing olomorasib, an experimental KRAS G12C inhibitor, combined with immunotherapy demonstrated median progression-free survival of 14.5 months in advanced NSCLC. Lilly expects Phase 3 data in 2027. Olomorasib is not yet approved but has received Breakthrough Therapy designation from the FDA.

AstraZeneca announced positive results from a Phase III study of its combination treatment for bladder cancer. The study met its primary endpoint, showing improved outcomes. The company's shares have seen a 3.04% increase year-to-date, despite a recent 1.20% decline. The news could impact investor sentiment and trading activity.

Capstone Energy+ (NASDAQ: CEPL) is developing tech upgrades for data centers, including 800-volt DC systems and a 250-kW engine. The company aims to reduce emissions and improve efficiency, targeting 90% overall efficiency. Data centers present complex sales cycles, but Capstone sees opportunities in smaller facilities. The company's systems offer flexibility and redundancy compared to fuel cells, potentially improving margins.

Apple (AAPL) will report Q4 earnings on Nov 2, with expected revenue of $113.2B and EPS of $1.98. Analyst Gene Munster raised FY27 iPhone Duo shipment forecasts to 20M units, potentially adding $8B in revenue. The company launched its first foldable iPhone, with strong initial demand reported, though supply constraints persist for Pro models.

Russia and Kazakhstan are selling gold reserves, with Russia reducing its holdings by 62 tonnes since January and Kazakhstan planning to reduce its gold reserves to 75% of total reserves. China's central bank is a major buyer of Russian gold. Poland, however, continues to increase its gold reserves. Experts suggest these transactions will have a negligible impact on global gold prices, which have seen significant increases in recent years but have weakened in 2026.